Monica Morrow joins Memorial Sloan-Kettering Cancer Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

NEW YORK-Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

“We are very fortunate that Dr. Morrow, one of the country’s preeminent breast cancer surgeons, has joined our staff,” said Peter Scardino, MD, chair of the Department of Surgery. “Dr. Morrow is a superb physician, a distinguished spokesperson for breast cancer, and brings years of experience in surgical oncology to her new role.”

For more than 20 years, Dr. Morrow has been a leader in the treatment and prevention of breast cancer. After completing her surgical oncology training at MSKCC, she led the University of Chicago Hospital and Northwestern Memorial Hospital’s clinical breast programs. She served as co-principal investigator of Northwestern University’s Specialized Program of Research Excellence in Breast Cancer and, in 1996, received one of three inaugural grants from the Department of Defense Center for Excellence to increase access to modern multidisciplinary breast cancer care.

Prior to her appointment at MSKCC, she was chairman of surgical oncology at Fox Chase Cancer Center where she held the G. Willing “Wing” Pepper Chair in Cancer Research.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content